SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:lup.lub.lu.se:98405667-81dd-4a1c-a171-3a21f3f797b1"
 

Sökning: id:"swepub:oai:lup.lub.lu.se:98405667-81dd-4a1c-a171-3a21f3f797b1" > Clinical validity o...

Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework

Wolters, E. E. (författare)
Vrije Universiteit Amsterdam,Amsterdam UMC - Vrije Universiteit Amsterdam
Dodich, A. (författare)
University of Trento,University of Geneva
Boccardi, M. (författare)
German Center for Neurodegenerative Diseases (DZNE), Bonn
visa fler...
Corre, J. (författare)
University of Geneva
Drzezga, A. (författare)
German Center for Neurodegenerative Diseases (DZNE), Bonn,University of Cologne,Jülich Research Centre
Hansson, O. (författare)
Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups,Skåne University Hospital
Nordberg, A. (författare)
Karolinska Institutet,Karolinska Institute
Frisoni, G. B. (författare)
Geneva University Hospital,University of Geneva
Garibotto, V. (författare)
University of Geneva
Ossenkoppele, R. (författare)
Lund University,Lunds universitet,Klinisk minnesforskning,Forskargrupper vid Lunds universitet,Clinical Memory Research,Lund University Research Groups,Amsterdam UMC - Vrije Universiteit Amsterdam,Vrije Universiteit Amsterdam
visa färre...
 (creator_code:org_t)
2021-02-06
2021
Engelska 13 s.
Ingår i: European Journal of Nuclear Medicine and Molecular Imaging. - : Springer Science and Business Media LLC. - 1619-7070 .- 1619-7089. ; 48:7, s. 2097-2109
  • Forskningsöversikt (refereegranskat)
Abstract Ämnesord
Stäng  
  • Purpose: In 2017, the Geneva Alzheimer’s disease (AD) Biomarker Roadmap initiative adapted the framework of the systematic validation of oncological diagnostic biomarkers to AD biomarkers, with the aim to accelerate their development and implementation in clinical practice. With this work, we assess the maturity of [18F]flortaucipir PET and define its research priorities. Methods: The level of maturity of [18F]flortaucipir was assessed based on the AD Biomarker Roadmap. The framework assesses analytical validity (phases 1–2), clinical validity (phases 3–4), and clinical utility (phase 5). Results: The main aims of phases 1 (rationale for use) and 2 (discriminative ability) have been achieved. [18F]Flortaucipir binds with high affinity to paired helical filaments of tau and has favorable kinetic properties and excellent discriminative accuracy for AD. The majority of secondary aims of phase 2 were fully achieved. Multiple studies showed high correlations between ante-mortem [18F]flortaucipir PET and post-mortem tau (as assessed by histopathology), and also the effects of covariates on tracer binding are well studied. The aims of phase 3 (early detection ability) were only partially or preliminarily achieved, and the aims of phases 4 and 5 were not achieved. Conclusion: Current literature provides partial evidence for clinical utility of [18F]flortaucipir PET. The aims for phases 1 and 2 were mostly achieved. Phase 3 studies are currently ongoing. Future studies including representative MCI populations and a focus on healthcare outcomes are required to establish full maturity of phases 4 and 5.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Neurologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Neurology (hsv//eng)

Nyckelord

Alzheimer’s disease
Biomarker-based diagnosis
PET
Strategic roadmap
[F]flortaucipir

Publikations- och innehållstyp

for (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy